E. coli Outbreak in Canada
Provides Study Opportunity for Company
CALGARY, CANADA-An outbreak of E. coli has provided an unique opportunity for a pharmaceutical company developing a drug to treat the bacteria. Canadian-based Synsorb Biotech was asked to supply its Synsorb Pk(R) to hospitals in Walkerton, Ontario, where hundreds of residents have become ill after drinking contaminated water. The Canadian Health Authorities issued approval for emergency use of the treatment designed to prevent serious complications associated with verotoxigenic E. coli (VTEC) infections. Synsorb Pk(R) attaches to the bacteria's toxins and neutralizes them allowing safe passage through the digestive tract. According to Synsorb, approximately 10% of the patients who become infected with E. coli develop Hemolytic Uremic Syndrome (HUS), a potentially deadly kidney disease. Consequently, the treatment has been given fast track product designation by the US Food and Drug Administration (FDA). Synsorb has been delayed producing clinical trial results because large-scale outbreaks are rare.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
